Vasculitis & polymyalgia rheumatica

Prognosis and Long‐Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis

Arthritis RheumatolPublished Retrospective cohort study

Authors' conclusion

Stenotic LVV accounts for less than 10% of GCA and is associated with poor vascular prognosis.

Study context

Population
Patients with giant cell arteritis (GCA) with stenotic large vessel-vasculitis (LVV)198 (6.3%) with stenotic LVV
Participants
3,149 patients
Outcome
Long-term outcome and prognosis (vascular complications) of GCA with stenotic LVV
Methodological detailsmulticentre, hierarchical clustering on principal components, logistic regression
  • Multicentre
  • Hierarchical clustering on principal components
  • Logistic regression

Main finding

As reported in the abstract

Cumulative incidence of vascular complications

Cumulative incidence at 1 year

13.1%

95% CI 8.9–18.3

Cumulative incidence at 5 years

17.3%

95% CI 12.3–22.9

Cumulative incidence at 10 years

19.5%

95% CI 14.3–25.4

Observational data: associations, not effects.

Further findings

Factors associated with vascular complication (multivariate)

HR (95% CI)P value
Age at diagnosis1.06 (1.03–1.10)P = 0.0004
Vertebral involvement1.87 (1.03–3.40)P = 0.039

Vascular complications by type

Stroke (main complication)
31%
Limb ischemia
21%
MI
4%
Mesenteric ischemia
2%

Stenotic LVV localisation

Subclavian artery
63%
Carotid artery
58%
Vertebral artery
37%
Axillary artery
33%
Femoral artery
30%
Mesenteric arteries
13%

Hierarchical clustering

Cluster 1 (n = 123; 62%): older patients, more arteritic anterior ischemic optic neuropathy (P = 0.04), vertebral artery stenosis, higher mortality rate (P < 0.044)
  • Three clusters identified

Original publication

Prognosis and Long‐Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis. Arthritis Rheumatol. Published 25 March 2026. doi:10.1002/art.70101

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.